porcine antilymphocyte globulin

Porcine antilymphocyte globulin (p-ALG), also referred to as porcine antithymocyte globulin (p-ATG), is a purified, swine-derived polyclonal IgG antibody preparation directed against human T lymphocytes. It is produced by immunizing healthy pigs with human thymocytes or peripheral blood lymphocytes, followed by purification of the immunoglobulin fraction. p-ALG acts as an immunosuppressive agent primarily by depleting T lymphocytes through complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and apoptosis, as well as by masking surface antigens and inhibiting T-cell activation. In China, where horse-derived antithymocyte globulin (h-ATG) has been unavailable since 2000, p-ALG is widely used as a first-line immunosuppressive therapy (IST) in combination with cyclosporine A for patients with severe aplastic anemia (SAA) who are ineligible for hematopoietic stem cell transplantation. It is also utilized in conditioning regimens for bone marrow and organ transplantation (such as kidney transplantation) to prevent graft-versus-host disease (GVHD) and graft rejection.

Brand names

Anti-lymphocyte Immunoglobulin

Other names

anti-human T lymphocyte porcine immunoglobulinporcine anti-human lymphocyte immunoglobulinporcine antithymocyte globulinswine antilymphocyte globulinswine antithymocyte globulin